ID25592A - Mikropartikel lipofilik yang mengandung obat protein atau anti gen formulasi yang terdiri dari mikropartikel tersebut - Google Patents

Mikropartikel lipofilik yang mengandung obat protein atau anti gen formulasi yang terdiri dari mikropartikel tersebut

Info

Publication number
ID25592A
ID25592A IDW20001816A ID20001816A ID25592A ID 25592 A ID25592 A ID 25592A ID W20001816 A IDW20001816 A ID W20001816A ID 20001816 A ID20001816 A ID 20001816A ID 25592 A ID25592 A ID 25592A
Authority
ID
Indonesia
Prior art keywords
microparticles
lipofilic
contain drugs
anti gen
formulation consist
Prior art date
Application number
IDW20001816A
Other languages
English (en)
Indonesian (id)
Inventor
Myung-Jin Kim
Sun-Jin Kim
Kyu-Chan Kwon
Joon Kim
Original Assignee
Lg Chemical Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from KR1019990001232A external-priority patent/KR100329336B1/ko
Priority claimed from KR1019990059776A external-priority patent/KR100359252B1/ko
Application filed by Lg Chemical Ltd filed Critical Lg Chemical Ltd
Publication of ID25592A publication Critical patent/ID25592A/id

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/19—Cytokines; Lymphokines; Interferons
    • A61K38/21—Interferons [IFN]
    • A61K38/212—IFN-alpha
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/22—Hormones
    • A61K38/27—Growth hormone [GH], i.e. somatotropin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/39—Medicinal preparations containing antigens or antibodies characterised by the immunostimulating additives, e.g. chemical adjuvants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/10—Dispersions; Emulsions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/10—Dispersions; Emulsions
    • A61K9/107—Emulsions ; Emulsion preconcentrates; Micelles
    • A61K9/113—Multiple emulsions, e.g. oil-in-water-in-oil
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1605—Excipients; Inactive ingredients
    • A61K9/1617—Organic compounds, e.g. phospholipids, fats
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1605—Excipients; Inactive ingredients
    • A61K9/1629—Organic macromolecular compounds
    • A61K9/1652—Polysaccharides, e.g. alginate, cellulose derivatives; Cyclodextrin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1605—Excipients; Inactive ingredients
    • A61K9/1629—Organic macromolecular compounds
    • A61K9/1658—Proteins, e.g. albumin, gelatin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
    • A61K9/5005—Wall or coating material
    • A61K9/5015—Organic compounds, e.g. fats, sugars
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A61P31/06—Antibacterial agents for tuberculosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/10—Antimycotics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/16—Antivirals for RNA viruses for influenza or rhinoviruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/20—Antivirals for DNA viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P33/00—Antiparasitic agents
    • A61P33/02—Antiprotozoals, e.g. for leishmaniasis, trichomoniasis, toxoplasmosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/48—Drugs for disorders of the endocrine system of the pancreatic hormones
    • A61P5/50—Drugs for disorders of the endocrine system of the pancreatic hormones for increasing or potentiating the activity of insulin

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Epidemiology (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Virology (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Molecular Biology (AREA)
  • Immunology (AREA)
  • Endocrinology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Pulmonology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Zoology (AREA)
  • Dispersion Chemistry (AREA)
  • Diabetes (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Biotechnology (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Mycology (AREA)
  • Biophysics (AREA)
  • Microbiology (AREA)
  • Medicinal Preparation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
IDW20001816A 1999-01-18 2000-01-14 Mikropartikel lipofilik yang mengandung obat protein atau anti gen formulasi yang terdiri dari mikropartikel tersebut ID25592A (id)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
KR1019990001232A KR100329336B1 (ko) 1999-01-18 1999-01-18 히아루론산을 이용한 단백질 약물의 서방성 미세 입자 제형
KR1019990059776A KR100359252B1 (ko) 1999-12-21 1999-12-21 항원을 포함하는 고체상 미세입자 및 이를 포함하는 제제

Publications (1)

Publication Number Publication Date
ID25592A true ID25592A (id) 2000-10-19

Family

ID=26634599

Family Applications (1)

Application Number Title Priority Date Filing Date
IDW20001816A ID25592A (id) 1999-01-18 2000-01-14 Mikropartikel lipofilik yang mengandung obat protein atau anti gen formulasi yang terdiri dari mikropartikel tersebut

Country Status (20)

Country Link
EP (2) EP1071407B1 (hu)
JP (1) JP3802348B2 (hu)
CN (1) CN1142772C (hu)
AR (1) AR043272A1 (hu)
AU (1) AU751200B2 (hu)
BG (1) BG65233B1 (hu)
BR (1) BR0004152A (hu)
CA (1) CA2324403C (hu)
DK (1) DK1071407T3 (hu)
ES (1) ES2505696T3 (hu)
HK (1) HK1036415A1 (hu)
HU (1) HUP0101040A3 (hu)
ID (1) ID25592A (hu)
IL (1) IL138468A0 (hu)
MY (1) MY125541A (hu)
NZ (1) NZ506975A (hu)
PL (1) PL200954B1 (hu)
TR (1) TR200002683T1 (hu)
TW (1) TWI260988B (hu)
WO (1) WO2000041682A1 (hu)

Families Citing this family (24)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR100236771B1 (ko) * 1997-04-01 2000-02-01 성재갑 히아루론산을 이용한 약물의 서방성 미세입자 제형
CN1174741C (zh) * 1999-09-21 2004-11-10 Rtp药品公司 生物活性物质的表面改性微粒组合物
AU2006201100B2 (en) * 1999-09-21 2009-09-24 Jagotec Ag Surface modified particulate compositions of biologically active substances
US7582311B1 (en) * 1999-10-15 2009-09-01 Genentech, Inc. Injection vehicle for polymer-based formulations
AU2001264789A1 (en) * 2000-06-08 2001-12-17 Eli Lilly And Company Protein powder for pulmonary delivery
US6998393B2 (en) * 2000-06-23 2006-02-14 Biopharm Solutions, Inc. Aquespheres, their preparation and uses thereof
JP4685350B2 (ja) * 2001-07-26 2011-05-18 オタゴ イノベイション リミティド 抗原性組成物
JP4683319B2 (ja) * 2003-02-19 2011-05-18 武田薬品工業株式会社 徐放性製剤用の分散剤
EP1595549A4 (en) * 2003-02-19 2010-09-22 Takeda Pharmaceutical DISPERSING AGENT FOR SUSTAINED RELEASE PREPARATIONS
CA2555921A1 (en) * 2004-02-13 2005-09-15 Nod Pharmaceuticals, Inc. Therapeutic calcium phosphate particles and methods of making and using same
WO2005120484A1 (ja) * 2004-06-09 2005-12-22 Kurume University グレリンの生理学的機能のレギュレーター
KR100729954B1 (ko) * 2004-12-01 2007-06-20 주식회사 엘지생명과학 Ｓｅｃ１ 변이 단백질의 제형 및 그것의 제형화 방법
WO2007025441A1 (en) 2005-08-29 2007-03-08 Tuo Jin Polysaccharide microparticles containing biological agents: there preparation and applications
US20090023629A1 (en) * 2005-12-23 2009-01-22 Altus Pharmaceuticals Inc. Compositions comprising polycation-complexed protein crystals and methods of treatment using them
FR2904219B1 (fr) * 2006-07-28 2010-08-13 Flamel Tech Sa Microparticules a base de copolymere amphiphile et de principe(s) actif(s) a liberation modifiee et formulations pharmaceutiques en contenant
CN101618213B (zh) * 2008-07-03 2013-01-23 武汉生物制品研究所有限责任公司 麻疹腮腺炎乙型脑炎联合减毒活疫苗及其制备方法
US20120135039A1 (en) * 2008-10-08 2012-05-31 Aldwell Frank E Oral Vaccines for Producing Mucosal Immunity
WO2014206857A1 (en) * 2013-06-28 2014-12-31 Universitat Autonoma De Barcelona Oil-in-water formulations of mycobacterium and uses thereof
CN103923881B (zh) * 2013-08-09 2016-04-06 北京科兴生物制品有限公司 甲肝病毒单克隆抗体及其应用
EP3125932A1 (en) 2014-04-03 2017-02-08 Boehringer Ingelheim Vetmedica, Inc. Porcine epidemic diarrhea virus vaccine
GB201716419D0 (en) 2017-10-06 2017-11-22 Univ Central Lancashire Solid composition
MX2022003446A (es) 2019-09-23 2022-07-13 Dds Res Inc Composiciones de vesiculas lipidicas con agentes potenciadores de la penetracion.
CN112933044A (zh) * 2020-12-17 2021-06-11 太阳雨林（厦门）生物医药有限公司 一种用于恶性肿瘤治疗的载药油制剂及制备方法和应用
CN112961221B (zh) * 2021-02-28 2022-05-17 长春祈健生物制品有限公司 一种水痘-带状疱疹病毒糖蛋白e胞外区蛋白的制备方法

Family Cites Families (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5059421A (en) * 1985-07-26 1991-10-22 The Liposome Company, Inc. Preparation of targeted liposome systems of a defined size distribution
JPH01287041A (ja) 1988-05-13 1989-11-17 Rooman Kogyo:Kk 徐放性製剤
JP2513276B2 (ja) 1988-06-10 1996-07-03 日本電気株式会社 位相同期ル―プ
US5416017A (en) 1990-05-18 1995-05-16 The Scripps Research Institute Cholera toxin gene regulated by tissue-specific promoters
DE4107153A1 (de) 1991-03-06 1992-09-10 Gregor Cevc Praeparat zur wirkstoffapplikation in kleinsttroepfchenform
DE69128455T2 (de) 1990-11-06 1998-06-18 Inst Nacional De Engenharia E Liposomale Mittel sowie Verfahren zu deren Herstellung
WO1992014449A1 (en) * 1991-02-20 1992-09-03 Nova Pharmaceutical Corporation Controlled release microparticulate delivery system for proteins
DE69426570T2 (de) * 1993-11-03 2001-08-23 Isomed Inc Mizelleförmige feinteilige pharmazeutische zusammensetzungen
US5858398A (en) * 1994-11-03 1999-01-12 Isomed Inc. Microparticular pharmaceutical compositions
KR100201352B1 (ko) 1995-03-16 1999-06-15 성재갑 단일주사 백신 제형
KR100236771B1 (ko) * 1997-04-01 2000-02-01 성재갑 히아루론산을 이용한 약물의 서방성 미세입자 제형
AU740111B2 (en) * 1996-09-27 2001-11-01 Jagotec Ag Hyaluronic drug delivery system
US6096291A (en) 1996-12-27 2000-08-01 Biovector Therapeutics, S.A. Mucosal administration of substances to mammals
AU2001280934A1 (en) * 2000-07-28 2002-02-13 Alliance Pharmaceutical Corp. Methods and compositions to upregulate, redirect or limit immune responses to bioactive compounds

Also Published As

Publication number Publication date
JP3802348B2 (ja) 2006-07-26
ES2505696T3 (es) 2014-10-10
EP1071407A1 (en) 2001-01-31
CN1293568A (zh) 2001-05-02
EP1071407B1 (en) 2014-07-23
PL342967A1 (en) 2001-07-16
TWI260988B (en) 2006-09-01
WO2000041682A1 (en) 2000-07-20
BR0004152A (pt) 2000-11-21
CA2324403A1 (en) 2000-07-20
DK1071407T3 (da) 2014-10-20
CN1142772C (zh) 2004-03-24
EP2481401A1 (en) 2012-08-01
PL200954B1 (pl) 2009-02-27
MY125541A (en) 2006-08-31
NZ506975A (en) 2004-01-30
HK1036415A1 (en) 2002-01-04
AU751200B2 (en) 2002-08-08
JP2002534459A (ja) 2002-10-15
EP1071407A4 (en) 2009-05-20
BG65233B1 (bg) 2007-09-28
IL138468A0 (en) 2001-10-31
BG104742A (en) 2001-07-31
CA2324403C (en) 2005-12-13
AR043272A1 (es) 2005-07-27
AU3080500A (en) 2000-08-01
HUP0101040A3 (en) 2005-11-28
HUP0101040A2 (hu) 2001-08-28
TR200002683T1 (tr) 2000-12-21

Similar Documents

Publication Publication Date Title
ID25592A (id) Mikropartikel lipofilik yang mengandung obat protein atau anti gen formulasi yang terdiri dari mikropartikel tersebut
CY2014003I1 (el) Φαρμακοτεχνικες μορφες εχινοκανδινης που περιεχουν επιφανειοδραστικα που σχηματιζουν μικκυλιο
PT1207867E (pt) Formas de administracao farmaceuticas orais retardadas contendo tramadol
ATE447947T1 (de) Pharmazeutische zubereitungen zur behandlung von insulinresitenz
EE200200357A (et) Ravimaine suurenenud kontsentratsioone andvad farmatseutilised kompositsioonid
PT1221917E (pt) Dispositivo para ministrar medicamentos
EE200200349A (et) Antiprogestiinsete omadustega ravimite manustamise vahendid
DE602004020901D1 (de) System zur Einführung von mehreren Medizinprodukten
ATE512163T1 (de) Verabreichung von mitteln zur behandlung von entzündungen
PT1221918E (pt) Administracao de drogas sub-tenon
IS5245A (is) Lyfjablanda úr ómeprasól
PL363507A1 (en) Pharmaceutical uses of bisphosphonates
IS7691A (is) Lyfjasamsetningar til að meðhöndla æxli
EE200100259A (et) Moksifloksatsiini farmatseutiline preparaat
NO20033384D0 (no) Farmasöytisk formulering
NO20033556D0 (no) Farmasöytiske preparater
NO20033785D0 (no) Farmasöytisk formulering
GB0202633D0 (en) Stabilization of protein preparations
NO20055010D0 (no) Preparater inneholdende laktulose for behandling av potavirusinfeksjoner
ID25535A (id) Komposisi batangan yang terdiri dari tetesan-tetesan pelunak yang terperangkap terdispersi padanya
NO20044916L (no) Preparater av sulfinylacetamid
NO20035627D0 (no) Farmasöytisk formulering
NO20013507L (no) Blandinger for behandling av inflammatoriske reaksjoner
HUP0600778A3 (en) Synthetic human peptides and pharmaceutical compositions comprising them for the treatment of systemic lupus erythematosus
PT1239862E (pt) Preparacao farmaceutica contendo citostaticos e aceitadores de electroes para o tratamento de cancro